(KRON) Kronos Bio - Ratings and Ratios

Kronos Bio, Inc. (NASDAQ: KRON) is a clinical-stage biopharmaceutical company specializing in the development of targeted cancer therapies. The company focuses on addressing aggressive cancers with high unmet medical needs, leveraging its expertise in small molecule inhibitors. Its lead candidate, KB-0742, is an oral cyclin-dependent kinase 9 (CDK9) inhibitor currently in Phase 2 clinical trials for MYC-amplified solid tumors, which are known for their poor prognosis. Additionally, KB-9558 targets a core oncogenic transcription factor that drives multiple myeloma, a type of blood cancer. Kronos Bio was founded in 2017 and operates from its headquarters in San Mateo, California, with a strong emphasis on precision medicine and biomarker-driven approaches.

The company’s stock exhibits a 20-day average volume of 190,023 shares, with a last price of $0.95. Its 20-day SMA stands at $0.98, while the 50-day and 200-day SMAs are both $0.98 and $1.01, respectively, indicating a recent decline in price. The ATR of $0.05 reflects low volatility. From a fundamental perspective, Kronos Bio has a market capitalization of $57.32 million, with a price-to-book ratio of 0.51, suggesting the stock is undervalued relative to its book value. The price-to-sales ratio of 5.81 indicates high expectations for future revenue growth. However, the company’s return on equity (RoE) is -77.02%, highlighting significant losses.